


Algestone acetophenide

Chemical Properties

CAS No. :	24356-94-3
Formula:	C ₂₉ H ₃₆ O ₄
Molecular Weight:	448.59
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Algestone acetophenide (Neolutin) is progesterone that used in estrus synchronization and has been evaluated as an injectable contraceptive in combination with estradiol enanthate. It is also used therapeutically as a topical anti-inflammatory and is applied topically in the therapy of ACNE.
Targets(IC50)	Others,Progesterone Receptor
In vitro	Every 21 days or so, each female received a single dose of combined hormonal contraceptive (algestone acetophenide and 17-enanthate estradiol) in a total of five doses throughout the experiment. The physiological parameters were accessed by means of 13 blood samples from each female, whereas three were gathered during the baseline and 10 samples were collected during the treatment phase. The results showed that the contraceptive use provoked changes in hematological coagulation factors such as an increase in the amount of platelets ($p = 0.039$) and a reduction in both prothrombin ($p < 0.001$) and thromboplastin coagulation time ($p < 0.001$). These results are similar to what has been observed in human patients[1].

Solubility Information

Solubility	DMSO: 10.83 mg/mL (24.14 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2292 mL	11.146 mL	22.2921 mL
5 mM	0.4458 mL	2.2292 mL	4.4584 mL
10 mM	0.2229 mL	1.1146 mL	2.2292 mL
50 mM	0.0446 mL	0.2229 mL	0.4458 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Rodrigues R C , Belham F S , Garcia A , et al. Continuous Use of Combined Hormonal Contraceptive and the Effect on Blood Coagulation Factors in Female Capuchin Monkeys (*Sapajus libidinosus*)[[J]]. *International Journal of Endocrinology*, 2019, 2019:1-9.

Wang T, Lei Y, Sun J, et al. Targeting NANOS1 in triple-negative breast cancer: synergistic effects of digoxin and PD-1 inhibitors in modulating the tumor immune microenvironment. *Frontiers in Oncology*. 2025, 14: 1536406.

Coutinho EM, Spinola P, Tomaz G, Morais K, Nassar de Souza R, Sabino Pinho Neto J, de Barros Leal W, Bomfim Hippolito S, D'Aurea Abranches A. Efficacy, acceptability, and clinical effects of a low-dose injectable contraceptive combination of dihydroxyprogesterone acetophenide and estradiol enanthate. *Contraception*. 2000 Apr;61(4):277-80. PubMed PMID: 10899484.

Martínez GH, Castañeda A, Correa JE. Vaginal bleeding patterns in users of Perlutal, a once-a-month injectable contraceptive consisting of 10 mg estradiol enanthate combined with 150 mg dihydroxyprogesterone acetophenide. A trial of 5462 woman-months. *Contraception*. 1998 Jul;58(1):21-7. PubMed PMID: 9743892.

Coutinho EM, Spinola P, Barbosa I, Gatto M, Tomaz G, Morais K, Yazlle ME, de Souza RN, Pinho Neto JS, Leal Wde B, Leal C, Hippolito SB, Abranches AD. Multicenter, double-blind, comparative clinical study on the efficacy and acceptability of a monthly injectable contraceptive combination of 150 mg dihydroxyprogesterone acetophenide and 10 mg estradiol enanthate compared to a monthly injectable contraceptive combination of 90 mg dihydroxyprogesterone acetophenide and 6 mg estradiol enanthate. *Contraception*. 1997 Mar;55(3):175-81. PubMed PMID: 9115007.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481